Curaleaf, founded in 2010, has cemented its place as a major player in the rapidly growing cannabis sector, becoming one of the largest multi-state operators (MSOs) in the U.S. With its roots in providing medical cannabis to patients, the company has evolved into a dominant force, offering a wide range of products to both medical and recreational consumers. Now based in Stamford, Connecticut, Curaleaf has positioned itself as a leader in the industry, boasting an extensive network of cultivation and retail facilities that span 17 states.
The company’s growth has been fueled by its strategic vision and aggressive expansion plans. As of 2024, Curaleaf operates more than 149 dispensaries across the U.S., supported by sprawling cultivation sites that span millions of square feet. The company’s product portfolio includes everything from flower to edibles, vapes, tinctures, and other cannabis-infused products, catering to a wide variety of consumer needs. Financially, Curaleaf’s momentum is unmistakable—reporting revenues of over $1 billion in 2023, the company has emerged as one of the top earners in the cannabis space, reflecting the increasing consumer demand for cannabis products across the country.
Curaleaf’s success can be largely attributed to its leadership team. Executive Chairman Boris Jordan and CEO Matt Darin have guided the company through a series of strategic acquisitions and partnerships, allowing it to expand its market reach. Among its notable moves was the acquisition of smaller companies like Grassroots and Select, which boosted Curaleaf’s presence in key markets. This aggressive growth strategy has not only solidified its standing among MSOs but has also helped Curaleaf emerge as one of the most recognized brands in the cannabis industry. Recently, the board appointed Boris Jordan as Chairman and CEO, while Matt will retire, but stay on as Special Advisor through 2024 year-end.
Beyond its business success, Curaleaf is also leading efforts in cannabis policy reform. The company has been vocal in advocating for federal cannabis legalization and the broader normalization of cannabis use, both for medical and recreational purposes. As the cannabis industry continues to gain legitimacy and acceptance, Curaleaf’s focus on expansion, innovation, and policy reform will likely keep it at the forefront of the evolving market, where it remains a pivotal player shaping the future of cannabis in the U.S. and beyond.